Altis Labs, Inc. (Altis), an innovative computational imaging firm, spearheads a worldwide coalition to push for the use of digital twins in clinical trials. This group aims to change the clinical trial design, speed up timelines, and lower failure rates for new cancer treatments.
Digital twins, or virtual replicas of physical systems, enable real-time monitoring and manipulation. In healthcare, professionals use them to simulate patient responses to treatments.
AstraZeneca and Bayer Pharmaceuticals apply these predictions to refine statistical analyses. This enhances treatment assessment accuracy and speeds up candidate prioritisation. Altis’ flagship platform, Nota, helps biopharma sponsors analyse imaging data from ongoing and past trials using AI models. These models forecast disease progression for patients, forming a virtual control group of digital twins. The project has been met with great excitement as it leverages AI tools to improve patient outcomes while building on Altis’ success in developing a substantial cancer imaging database.
AstraZeneca and Bayer Pharmaceuticals, as early adopters, have exclusive access to AI models through Nota for four clinical trials. DIGITAL, Canada’s top Innovation Cluster for digital technologies, backs this $5.7 million project.
The transformative potential of AI-based digital twins to provide insights beyond traditional tumour measurements is clear, reinforcing the crucial role of clinical trials. This initiative, merging Canada’s AI capabilities and healthcare systems, plays a significant role in adopting clinical research tools. The ultimate aim is to revolutionise therapeutic development and enhance the quality and accessibility of cancer care in Canada.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
